<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.business-standard.com/article/pti-stories/lupin-gets-usfda-nod-for-generic-chronic-asthma-treatment-drug-119110801367_1.html"/>
    <meta property="og:site_name" content="Business-Standard"/>
    <meta property="article:published_time" content="2019-11-08T12:20:00+00:00"/>
    <meta property="og:title" content="Lupin's prophylaxis and chronic asthma treatment drug gets USFDA nod"/>
    <meta property="og:description" content="The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added."/>
  </head>
  <body>
    <article>
      <h1>Lupin's prophylaxis and chronic asthma treatment drug gets USFDA nod</h1>
      <h2>The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.</h2>
      <address><time datetime="2019-11-08T12:20:00+00:00">08 Nov 2019, 12:20</time> by <a rel="author">Press Trust of India</a></address>
      <p>Domestic pharma firm Lupin on Friday said it has received approval from the US health regulator for its generic Zileuton extended-release tablets used as prophylaxis and in treatment of chronic <a href="https://www.business-standard.com/topic/asthma">asthma.</a></p>
      <p>The approval by the US Food and Drug Administration (USFDA) is for Zileuton extended-release tablets of strength 600 mg, which is the generic equivalent of Zyflo CR of Chiesi USA, Inc, Lupin said in a regulatory filing.</p>
      <p>The medicine is indicated for prophylaxis and treatment of chronic <a href="https://www.business-standard.com/topic/asthma">asthma </a>in adults and children 12 years of age and older, it added.</p>
      <p>Citing IQVIA MAT September 2019 data, the company said Zileuton extended-release tablets, 600 mg had annual sales of approximately $43 million in the US.</p>
    </article>
  </body>
</html>